Tumefactive Multiple Sclerosis Lesions Under Fingolimod Treatment

Neurology - United States
doi 10.1212/wnl.0b013e3182735cb3
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

A Case of Tumefactive Multiple Sclerosis Resembling Malignant Glioma

Japanese Journal of Neurosurgery
SurgeryNeurology
2017English

Debate on the Treatment of Multiple Sclerosis: Experience From an Intractable Multiple Sclerosis Case With Rebound Syndrome After Fingolimod Cessation

Clinical and Experimental Neuroimmunology
NeuroscienceNeurologyImmunologyMicrobiology
2019English

Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study

Multiple Sclerosis International
Neurology
2015English

Myeloid Cells as Target of Fingolimod Action in Multiple Sclerosis

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2015English

A Case of Pediatric Multiple Sclerosis Presenting With a Tumefactive Demyelinating Lesion

Clinical Neurology
Neurology
2017English

Fingolimod (FTY720) as an Anti-Multiple Sclerosis Oral Ultimate Therapy

Biosciences Biotechnology Research Asia
BiotechnologyAgronomyCrop ScienceDrug Discovery
2015English

Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two-Year Experience

Multiple Sclerosis Journal – Experimental, Translational and Clinical
2017English

Extensive Multiple Sclerosis Reactivation After Switching From Fingolimod to Rituximab

Case Reports in Neurological Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy